'Crispr' dough: Genome-editing start-up raises $25M in series A
By Cormac Sheridan
Thursday, April 24, 2014
Crispr Therapeutics AG, a start-up formed by the co-inventor of the CRISPR/Cas9 genome-editing technology, closed a $25 million series A round.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.